$0.18+0.01 (+5.99%)
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States.
Azitra, Inc. in the Healthcare sector is trading at $0.18 with a market capitalization of $3M. Wall Street consensus targets $0.78 (2 analysts), implying a +337.9% move over the next 12 months. The stock is currently near its 52-week low of $0.10, remaining 47.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$3.93Mβ | -$2.23Mβ | -$2.77Mβ | -$2.87Mβ | -$3.10M |
| Net Income | -$3.93Mβ | -$2.23Mβ | -$2.76Mβ | -$2.89Mβ | -$3.07M |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04,...
US stocks look set to open higher in Monday's trading session ahead of a raft of earnings coming out
AZTR: Azitra Soars After First Patient Dosed in FDA Fast Track Trial
Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index adding 0.1%
Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal